Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart, Inc. develops oral recombinant pill vaccines based on a proprietary delivery platform. The clinical-stage biotechnology company’s programs include vaccine candidates for coronavirus, norovirus and influenza, as well as a therapeutic human papillomavirus vaccine as its first immune-oncology indication. Its pill-based vaccines are designed for oral administration, storage and shipping without refrigeration, and avoidance of needle-stick risk.
Vaxart news centers on clinical data and scientific publications, business updates, financial results, financing arrangements, collaborations, intellectual property around adenovirus and TLR3 agonist oral vaccination technology, and governance changes as the company advances its oral vaccine pipeline.
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant pill vaccines, has appointed W. Mark Watson as Lead Independent Director. Watson, a Certified Public Accountant with over 50 years of experience, including 40+ years at Deloitte, has served on Vaxart's Board since August 2022.
The company is implementing two significant governance changes: appointing Watson as Lead Independent Director and adopting a Director stock ownership policy to align Board interests with stockholders. Additionally, Vaxart is actively seeking stockholder approval for a reverse stock split, with voting deadline set for September 18, 2025, at 11:59 p.m. ET. The special stockholder meeting will be held virtually on September 19, 2025, at 8:30 a.m. PT.
Vaxart (OTCQX: VXRT) has reported promising Phase 1 data for its second-generation norovirus oral pill vaccine. The vaccine demonstrated a 25-fold increase in GII.4 fecal IgA response and a 10-fold increase in GI.I fecal IgA response over baseline with high-dose administration.
The second-generation constructs showed superior immunologic responses compared to first-generation versions, which previously demonstrated a 30% relative reduction in infection versus placebo in Phase 2b trials. The company's vaccine technology uniquely induces intestinal immunity, potentially offering stronger protection at the virus entry site.
With norovirus causing 685 million infections globally annually and representing a $10+ billion economic impact in the U.S., Vaxart is seeking partnerships to advance to Phase 2 trials by late 2025, with potential Phase 3 trials beginning in 2026.
Vaxart (NASDAQ:VXRT) announced the adjournment of its 2025 special meeting of stockholders to September 19, 2025. The meeting, which includes a critical reverse stock split proposal to maintain Nasdaq listing, was postponed to give shareholders more time to consider recent board changes, potential governance modifications, and upcoming company disclosures.
CEO Steven Lo emphasized the importance of maintaining Nasdaq listing for advancing the company's science and maximizing shareholder value. The virtual meeting will be accessible to stockholders of record as of July 29, 2025, who can vote until 11:59 p.m. ET on September 18, 2025.
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company specializing in oral recombinant pill vaccines, has announced its participation in the upcoming H.C. Wainwright Global Investment Conference.
Management will deliver their presentation on Monday, September 8, 2025, at 12:00 PM ET. The presentation will be accessible via webcast on the company's investor relations website, with a replay available for 30 days after the event. Investors can arrange meetings with management through their H.C. Wainwright representatives.
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant pill vaccines, announced the retirement of its Chairman Michael J. Finney, Ph.D. from the Board of Directors and Science and Technology Committee, effective September 30, 2025.
The Board of Directors will convene to discuss leadership succession, composition, and governance matters while considering stockholder feedback. The company aims to maintain its focus on advancing its scientific initiatives and oral pill vaccine platform development.
Vaxart (NASDAQ:VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, has received an extension from the Nasdaq Hearings Panel to regain compliance with the minimum bid price requirement. The company must meet three critical conditions: obtain stockholder approval for a reverse stock split by September 5, 2025, complete the reverse split by October 6, 2025, and demonstrate compliance with the Bid Price Rule by October 17, 2025.
During an August 14 hearing, Vaxart's management presented their compliance plan, highlighting modifications to their reverse stock split proposal, including a narrower split ratio range and reduced authorized shares. CEO Steven Lo emphasized the importance of maintaining Nasdaq listing for the company's future success.
Vaxart (OTCQX: VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, will host a virtual stockholder fireside chat on August 20, 2025, at 4:30 p.m. ET to discuss its reverse stock split proposal. Leading proxy advisory firms ISS and Glass Lewis have recommended stockholders support the proposal, which aims to regain Nasdaq compliance.
The company's management team will address stockholder questions during the event, with investors able to submit questions in advance. Stockholders of record as of July 29, 2025, can vote on the proposal until September 4, 2025.
[]Vaxart (OTCQX: VXRT) reported Q2 2025 financial results and provided significant updates across its vaccine pipeline. The company reported revenue of $39.7M (vs $6.4M in Q2 2024) and a net loss of $15.0M. Key developments include positive topline data from their second-generation norovirus vaccine trial, showing statistically significant increases in blocking antibodies (141% for GI.1 and 94% for GII.4) compared to first-generation constructs.
The company's COVID-19 Phase 2b trial enrolled approximately 5,000 participants before receiving a stop work order, with follow-up continuing for all dosed participants. Vaxart ended Q2 with $26.3M in cash and equivalents, projecting runway into 2026. The company will hold a special stockholder meeting on September 5, 2025, to vote on a potential reverse stock split to regain Nasdaq compliance.
Vaxart (OTCQX: VXRT) CEO Steven Lo has issued a critical letter to stockholders urging them to vote in favor of a reverse stock split proposal by September 4, 2025. The proposal aims to facilitate relisting on Nasdaq after the company's recent delisting. The letter outlines key benefits of a Nasdaq listing, including broader investor access, enhanced visibility, and improved financial flexibility.
The company provided updates on its clinical programs: The COVID-19 Phase 2b trial has enrolled approximately 5,000 participants before receiving a stop work order, with topline data expected in late 2026. Their Norovirus vaccine showed positive Phase 1 results, and their Avian Influenza candidate demonstrated 100% protection in preclinical studies. Vaxart has extended its cash runway into 2026.
Vaxart (OTCQX:VXRT) has scheduled its Q2 2025 business update and financial results conference call for August 13, 2025, at 4:30 p.m. ET, following the market close. The company will provide a comprehensive business update and report financial results for the quarter ended June 30, 2025.
Investors can access the conference call through a webcast or by dialing (877) 407-0832 for domestic calls or (201) 689-8433 for international calls using Conference ID 13755103. Written questions can be submitted in advance to ir@vaxart.com by August 12, 2025. A replay will be available on Vaxart's website after the event.